Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 5/20 | 0.48 |
| ▸ | AKR1B10 | O60218 | 4/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.45 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | CYBB | P04839 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL78103 | 1.00 | HCAR2 (0.53) | HCAR2IDO1AKR1B1AKR1B10CA12 | |
| SCHEMBL21678780 | 0.93 | HCAR2 (0.65) | HCAR2IDO1AKR1B1AKR1B10CA12 | |
| SCHEMBL78104 | 0.93 | HCAR2 (0.65) | HCAR2IDO1AKR1B1AKR1B10CA12 | |
| SCHEMBL21678700 | 0.92 | MAPT (0.52) | HCAR2IDO1AKR1B1AKR1B10CA12 | |
| SCHEMBL21678773 | 0.92 | AKR1B1 (0.47) | HCAR2IDO1AKR1B1AKR1B10CA12 | |
| SCHEMBL5176891 | 0.90 | IDO1 (0.46) | HCAR2IDO1AKR1B1AKR1B10CA12 | |
| SCHEMBL21678750 | 0.89 | APP (0.50) | HCAR2IDO1AKR1B1AKR1B10LMNA | |
| SCHEMBL21678777 | 0.87 | AKR1B1 (0.48) | HCAR2IDO1AKR1B1AKR1B10CA12 | |
| SCHEMBL5312883 | 0.87 | LMNA (0.67) | AKR1B1AKR1B10CA12CA4CA6 | |
| SCHEMBL5312885 | 0.87 | LMNA (0.67) | AKR1B1AKR1B10CA12CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4021933-B1 | THIOSUCCINYL-CROSSLINKED HEMOGLOBIN ANALOGS AND METHODS OF USE AND PREPARATION THEREOF | BILLION KING INTERNATIONAL LTD (HK) | 2024-10-09 | — | — | EP | claimed |
| US-11857605-B2 | Thiosuccinyl-crosslinked hemoglobin conjugates and methods of use and preparation thereof | BILLION KING INTERNATIONAL LIMITED (CN) | 2024-01-02 | — | — | US | claimed |
| US-11479597-B2 | Thiosuccinyl-crosslinked hemoglobin analogs and methods of use and preparation thereof | BILLION KING INTERNATIONAL LIMITED (CN) | 2022-10-25 | — | — | US | claimed |
| US-20220280616-A1 | Thiosuccinyl-crosslinked Hemoglobin Conjugates and Methods of Use and Preparation Thereof | BILLION KING INTERNATIONAL LIMITED (HK) | 2022-09-08 | — | — | US | claimed |
| US-20210061885-A1 | Thiosuccinyl-crosslinked Hemoglobin Analogs and Methods of Use and Preparation Thereof | BILLION KING INTERNATIONAL LIMITED (CN) | 2021-03-04 | — | — | US | claimed |
| EP-4021933-B1 | THIOSUCCINYL-CROSSLINKED HEMOGLOBIN ANALOGS AND METHODS OF USE AND PREPARATION THEREOF | BILLION KING INTERNATIONAL LTD (HK) | 2024-10-09 | — | — | EP | disclosed |
| US-11857605-B2 | Thiosuccinyl-crosslinked hemoglobin conjugates and methods of use and preparation thereof | BILLION KING INTERNATIONAL LIMITED (CN) | 2024-01-02 | — | — | US | disclosed |
| US-11692022-B2 | Thiosuccinyl-crosslinked hemoglobin analogs and methods of use and preparation thereof | BILLION KING INTERNATIONAL LIMITED (CN) | 2023-07-04 | — | — | US | disclosed |
| US-20230111100-A1 | Thiosuccinyl-crosslinked Hemoglobin Analogs and Methods of Use and Preparation Thereof | BILLION KING INTERNATIONAL LIMITED (HK) | 2023-04-13 | — | — | US | disclosed |
| US-11479597-B2 | Thiosuccinyl-crosslinked hemoglobin analogs and methods of use and preparation thereof | BILLION KING INTERNATIONAL LIMITED (CN) | 2022-10-25 | — | — | US | disclosed |
| US-20220280616-A1 | Thiosuccinyl-crosslinked Hemoglobin Conjugates and Methods of Use and Preparation Thereof | BILLION KING INTERNATIONAL LIMITED (HK) | 2022-09-08 | — | — | US | disclosed |
| US-20210061885-A1 | Thiosuccinyl-crosslinked Hemoglobin Analogs and Methods of Use and Preparation Thereof | BILLION KING INTERNATIONAL LIMITED (CN) | 2021-03-04 | — | — | US | disclosed |
| US-20110256187-A1 | BIOFILM-INHIBITORY COATINGS THAT RELEASE SALICYCLIC ACID BY HYDROLISIS | BAYER MATERIALSCIENCE LLC (US) | 2011-10-20 | — | — | US | disclosed |
| EP-2358777-A2 | BIOFILM-INHIBITORY COATINGS THAT RELEASE SALICYCLIC ACID BY HYDROLISIS | Bayer MaterialScience LLC (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010056345-A2 | BIOFILM-INHIBITORY COATINGS THAT RELEASE SALICYCLIC ACID BY HYDROLISIS | BAYER MATERIALSCIENCE LLC (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061885-A1 | Thiosuccinyl-crosslinked Hemoglobin Analogs and Methods of Use and Preparation Thereof | HBG1, HBG2, HBB | HCAR2 3037/4885IDO1 4205/4885AKR1B1 2336/4885 |
| US-11692022-B2 | Thiosuccinyl-crosslinked hemoglobin analogs and methods of use and preparation thereof | HBG1, HBG2, HBB | HCAR2 3037/4885IDO1 4205/4885AKR1B1 2336/4885 |
| US-20110256187-A1 | BIOFILM-INHIBITORY COATINGS THAT RELEASE SALICYCLIC ACID BY HYDROLISIS | MMP1, MMP11, MMP13 | HCAR2 6/4885IDO1 1019/4885AKR1B1 3302/4885 |
| US-20230111100-A1 | Thiosuccinyl-crosslinked Hemoglobin Analogs and Methods of Use and Preparation Thereof | HBG1, HBG2, HBB | HCAR2 3037/4885IDO1 4205/4885AKR1B1 2336/4885 |
| US-11479597-B2 | Thiosuccinyl-crosslinked hemoglobin analogs and methods of use and preparation thereof | HBG1, HBG2, HBB | HCAR2 3037/4885IDO1 4205/4885AKR1B1 2336/4885 |
| US-11857605-B2 | Thiosuccinyl-crosslinked hemoglobin conjugates and methods of use and preparation thereof | HBG1, HBG2, HBB | HCAR2 3018/4885IDO1 4252/4885AKR1B1 3204/4885 |
| US-20220280616-A1 | Thiosuccinyl-crosslinked Hemoglobin Conjugates and Methods of Use and Preparation Thereof | HBG1, HBG2, HBB | HCAR2 3018/4885IDO1 4252/4885AKR1B1 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.